Grifols stock rises 1.59% from prior report as Q3 focus holds
Published on 11/11/2026 at 18:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCash Flow And Debt Remain In Focus
- Grifols continues to attract attention for stronger cash generation and lower leverage.
- Management has kept its full-year guidance unchanged.
- Investors are watching the SPARTA study and the China albumin market.
Grifols stock traded at 11.48 euros on Lang & Schwarz at 18:20 CET on Wednesday, November 11, 2026. That compares with 11.30 euros in the relevant report published earlier the same day, a 1.59% increase between the two readings.
Cash Generation Supports Deleveraging
Grifols' third-quarter update kept cash generation and balance-sheet repair at the center of the investment case. The company reported stronger Biopharma growth, higher margins and improved free cash flow while maintaining its full-year guidance.
Free cash flow before mergers and acquisitions reached 298 million euros through September, while net leverage declined to 3.98 times adjusted EBITDA. Refinancing of 2027 obligations also extended the next significant maturity window to the fourth quarter of 2028.
Growth Drivers And Risks
Biopharma and immunoglobulin demand remain the main operating supports. Albumin weakness in China is a counterweight, leaving regional demand and channel conditions important variables for the fourth quarter.
Investors are also watching the Phase 3 SPARTA study of alpha-1 antitrypsin in emphysema. Grifols expects topline results by the end of the fourth quarter of 2026.
Grifols S.A. Key Facts
- Company: Grifols S.A.
- ISIN: ES0171996087
- Home exchange: Spanish Stock Exchange
- Latest quote: 11.48 euros on Lang & Schwarz at 18:20 CET on November 11, 2026
- Change from relevant report: 1.59% above 11.30 euros at 11:45 CET on November 11, 2026
- Sector: Healthcare
European investors are also tracking the IBEX 35 as Spanish equities respond to company-specific earnings signals and wider market moves.
